Oncology Treatments during the COVID-19 Pandemic in Israel: the ONCOR Study.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Dec 2021
Historique:
entrez: 26 12 2021
pubmed: 27 12 2021
medline: 4 1 2022
Statut: ppublish

Résumé

The increased susceptibility of cancer patients to coronavirus disease-2019 (COVID-19) infections and complications calls for special precautions while treating cancer patients during COVID-19 pandemics. Thus, oncology departments have had to implement a wide array of prevention measures. To address issues associated with cancer care during the COVID-19 pandemic and to assess the implementation of measures aimed at containment of COVID-19 diffusion while allowing continuation of quality cancer care. A national survey among oncology departments in Israel was conducted between 12 April 2020 and 14 April 2020. Eighteen heads of hospital-based oncology departments completed a self-report questionnaire regarding their institute's preparedness for treatment of cancer patients during the COVID-19 pandemic. In this national survey, prevention measures against COVID-19 spread were taken prior to patients' arrival and at arrival or while staying in the departments. Most participants (78-89%) reported using a quick triage of patients and caregivers prior to their entrance to the oncology units, limiting the entrance of caregivers, and reducing unnecessary visits to the clinic. Switching to oral therapies rather than intravenous ones when possible was considered by 82% and shortage in personal protective equipment was reported by five (28%) heads of oncology departments. Some differences between large and small/medium sized medical centers were observed regarding issues related to COVID-19 containment measures and changes in treatment. Oncology departments in Israel were able to prepare and adapt their services to guidelines and requirements related to the COVID-19 pandemic with little harm to their treatment capacity.

Sections du résumé

BACKGROUND BACKGROUND
The increased susceptibility of cancer patients to coronavirus disease-2019 (COVID-19) infections and complications calls for special precautions while treating cancer patients during COVID-19 pandemics. Thus, oncology departments have had to implement a wide array of prevention measures.
OBJECTIVES OBJECTIVE
To address issues associated with cancer care during the COVID-19 pandemic and to assess the implementation of measures aimed at containment of COVID-19 diffusion while allowing continuation of quality cancer care.
METHODS METHODS
A national survey among oncology departments in Israel was conducted between 12 April 2020 and 14 April 2020. Eighteen heads of hospital-based oncology departments completed a self-report questionnaire regarding their institute's preparedness for treatment of cancer patients during the COVID-19 pandemic.
RESULTS RESULTS
In this national survey, prevention measures against COVID-19 spread were taken prior to patients' arrival and at arrival or while staying in the departments. Most participants (78-89%) reported using a quick triage of patients and caregivers prior to their entrance to the oncology units, limiting the entrance of caregivers, and reducing unnecessary visits to the clinic. Switching to oral therapies rather than intravenous ones when possible was considered by 82% and shortage in personal protective equipment was reported by five (28%) heads of oncology departments. Some differences between large and small/medium sized medical centers were observed regarding issues related to COVID-19 containment measures and changes in treatment.
CONCLUSIONS CONCLUSIONS
Oncology departments in Israel were able to prepare and adapt their services to guidelines and requirements related to the COVID-19 pandemic with little harm to their treatment capacity.

Identifiants

pubmed: 34954913

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

759-765

Auteurs

Galit Hirsh-Yechezkel (G)

Cancer and Radiation Epidemiology Unit, affiliated with Tel Aviv University, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel.

Angela Chetrit (A)

Cancer and Radiation Epidemiology Unit, affiliated with Tel Aviv University, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel.

Sivan Ben Avraham (S)

Cancer and Radiation Epidemiology Unit, affiliated with Tel Aviv University, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel.

Abed Agbarya (A)

Department of Oncology, Bnai Zion Medical Center, Haifa, Israel.

Alexander Yakobson (A)

Legacy Heritage Oncology Center and Norton Institute, Soroka Medical Center, Beer Sheva, Israel.
Ben Gurion University of the Negev, Beer Sheva, Israel.

Noam Asna (N)

Department of Oncology Ziv Medical Center, Safed, Israel.

Gil Bar-Sela (G)

Cancer Center, Emek Medical Center, Afula, Israel.

Irit Ben-Aharon (I)

Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.

Noa Efrat Ben-Baruch (NE)

Department of Oncology, Kaplan Medical Center, Rehovot, Israel.
Department of Oncology, Nazareth Hospital, Nazareth, Israel.

Raanan Berger (R)

Cancer Center, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ronen Brenner (R)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Oncology Institute, Wolfson Medical Center, Holon, Israel.

Maya Gottfried (M)

Department of Oncology, Meir Medical Center, Kfar Saba, Israel.

Shani Paluch-Shimon (S)

Division of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
Division of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Raphael Pfeffer (R)

Ben Gurion University of the Negev, Beer Sheva, Israel.
Oncology Institute, Assuta Medical Center, Tel Aviv, Israel.

Aron Popovtzer (A)

Oncology Institute, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Larisa Ryvo (L)

Department of Oncology, Assuta Ashdod Academic Medical Center, Ashdod, Israel.

Valeriya Semenisty (V)

Oncology Unit, Hillel Yaffe Medical Center, Hadera, Israel.

Ayelet Shai (A)

Department of Oncology, Galilee Medical Center, Nahariya, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Katerina Shulman (K)

Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.
Oncology Unit, Carmel Medical Center, Haifa, Israel.

Jamal Zidan (J)

Department of Oncology Ziv Medical Center, Safed, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Ido Wolf (I)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH